Bukwang Pharmaceutical Co., Ltd.

KSE 003000.KS

Bukwang Pharmaceutical Co., Ltd. Goodwill for the year ending December 31, 2023: USD 674.87 K

Bukwang Pharmaceutical Co., Ltd. Goodwill is USD 674.87 K for the year ending December 31, 2023, a 2.37% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.
  • Bukwang Pharmaceutical Co., Ltd. Goodwill for the year ending December 31, 2022 was USD 659.26 K, a -4.95% change year over year.
  • Bukwang Pharmaceutical Co., Ltd. Goodwill for the year ending December 31, 2021 was USD 693.63 K, a -8.64% change year over year.
  • Bukwang Pharmaceutical Co., Ltd. Goodwill for the year ending December 31, 2020 was USD 759.23 K, a 10.54% change year over year.
  • Bukwang Pharmaceutical Co., Ltd. Goodwill for the year ending December 31, 2019 was USD 686.82 K, a -2.33% change year over year.
Key data
Date Goodwill Total Assets Current Liabilities Total Non-Current Liabilities
Market news
Loading...
KSE: 003000.KS

Bukwang Pharmaceutical Co., Ltd.

CEO Jae-Young Lee
IPO Date Sept. 29, 2005
Location South Korea
Headquarters 7, Sangdo-ro
Employees 554
Sector Health Care
Industries
Description

Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments. The company offers products in various therapeutic areas, including liver disease treatments, such as Levovir and Legalon; diabetic complication products comprising Dexid and Thioctacid; CNS disorder drugs consisting of Lonasen, Ixel, and Orfil; and respiratory disease treatments, which comprise Azeptin and Asima. It also provides OTC products; toothpastes, and hair and skin care goods; and nutritional supplements. In addition, the company offers products for antihistamines, hepatitis and gastrointestinal, sedative and antidote, anti-cancer, thyroid and osteoporosis, diabetes, obstetrics, urinogenital, cardiovascular, dermatology, obesity, pain relief, and muscle relaxant. Further, it provides products for bruises, skin and mucous membrane, rhinitis, cold symptoms, cough, phlegm and asthma, rheumatoid arthritis, osteoarthritis, pain caused by cold and fever, dysmenorrhea, NSAIDs, inflammation, joint inflammation, tinea pedis, infected wounds, dermatitis, antivirals-herpes, eczema, diarrhea, dyspepsia, sense of distension, anti-histamine, anti-ulcer, constipation, anemia, pregnant multivitamins, candidiasis, athlete's foot, onychomycosis, stomatitis, pimple, acne, physical fatigue, neuralgia, myalgia, and arthralgia. Additionally, the company offers medicines for period of lactation, rickets, night blindness, varicose vein, and sputum; and quasi drugs and medical devices, as well as health functional food. It also develops anti-diabetes compound with Melior Pharmaceuticals; and anti-cancer drugs with LSK BioPartners, as well as cell therapies using adult stem cells, as well as holds a license for a novel candidate to treat movement disorder in Parkinson's disease patients. The company was founded in 1960 and is based in Seoul, South Korea.

Similar companies

001060.KS

JW Pharmaceutical Corporation

USD 16.03

-1.15%

069620.KS

Daewoong pharmaceutical Co.,Ltd

USD 89.82

-0.84%

000640.KS

Dong-A Socio Holdings Co., Ltd.

USD 68.20

0.14%

000100.KS

Yuhan Corporation

USD 89.21

-4.31%

006280.KS

Green Cross Corporation

USD 108.37

-2.33%

StockViz Staff

January 15, 2025

Any question? Send us an email